Medtronic has received CE Mark certification for its MiniMed 780G system, a closed-loop insulin pump designed for the treatment of type 1 diabetics between the ages of 7 and 80-years-old.
The system uses the company’s SmartGuard algorithm and is designed to help stabilise blood sugar levels and further improve glucose control.
It enables the personalisation of glucose goals by offering adjustable target setting as low as 100 mg/dL (5.5 mmol/L).
The system also automates the delivery of both basal insulin and correction boluses every five minutes to help diabetic patients avoid highs and lows in blood sugar.
Additionally, the Bluetooth connectivity of the system enables users and their care partners to see real-time glucose data and trends on compatible iOS and Android smartphones via apps.
MedtronicDiabetes Group president and executive vice-president Sean Salmon said: “We wanted to design a system that further simplifies diabetes management and adapts to people’s lives with the goal of enhancing their experience in a seamless way.
“With this system, users will have an extra layer of coverage for those times they miscalculate their carbs or forget to pre-bolus with an algorithm that automatically corrects for high glucose when needed. We want to help people spend more time living their life and less time worrying about their diabetes management — we are confident this system delivers on that important goal.
The MiniMed 780G system is the latest addition to Medtronic portfolio of insulin pumps with smartphone connectivity via Bluetooth such as MiniMed 670G system and MiniMed 720G3.
The company expects to launch MiniMed 780G system later this year in select European countries. In the US, the system is currently approved for investigational use only.